Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average PT from Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been assigned an average rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $23.00.

Separately, Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 23,045 shares of company stock worth $177,242 over the last ninety days. 5.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its position in Aura Biosciences by 2.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after purchasing an additional 3,612 shares during the period. State Street Corp boosted its holdings in shares of Aura Biosciences by 3.7% during the 3rd quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after buying an additional 26,841 shares during the period. Wellington Management Group LLP acquired a new position in Aura Biosciences in the 3rd quarter valued at $1,037,000. Barclays PLC raised its holdings in Aura Biosciences by 256.5% in the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after acquiring an additional 43,897 shares during the period. Finally, Geode Capital Management LLC lifted its position in Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after acquiring an additional 39,379 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Stock Performance

Aura Biosciences stock opened at $7.50 on Monday. Aura Biosciences has a twelve month low of $6.63 and a twelve month high of $12.38. The firm has a market cap of $374.63 million, a PE ratio of -4.34 and a beta of 0.30. The firm’s 50 day moving average price is $7.66 and its two-hundred day moving average price is $8.67.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.